Payam Javan: U.S. President Donald Trump announced on July 21, 2026, a new tariff policy targeting imported generic drugs to encourage pharmaceutical companies to relocate their production facilities to the United States. Under the proposed plan, generic drugs imported into the country will face no tariffs for a two-year grace period starting in August 2026. However, a 100 percent tariff will be implemented in August 2028, which is scheduled to rise to 200 percent in August 2029.
In a statement shared on Truth Social, President Trump explained that the tariff structure serves as a penalty for pharmaceutical companies that choose not to establish manufacturing plants and equipment within the United States during the designated two-year window. He emphasized that the overarching objective of the policy is to safeguard the American public by securing the domestic drug supply. He also noted that existing policies regarding patented, branded, or innovative drugs would remain unchanged, claiming they have already successfully spurred unprecedented levels of domestic pharmaceutical facility construction.
The policy targets a critical segment of the American healthcare system, as generic medications account for more than 90 percent of all prescriptions filled in the United States, according to the U.S. Food and Drug Administration (FDA). Proponents of the tariff argue that the country’s heavy reliance on foreign-made generics exposes the public to severe risks, particularly in the event of global supply chain disruptions caused by geopolitical or economic conflicts. The administration has repeatedly warned that a self-sufficient domestic manufacturing base is essential to maintaining public health security during national emergencies.
This latest measure builds upon findings from a Commerce Department investigation conducted in April, which concluded that current import levels of pharmaceutical products and active ingredients pose a threat to both national security and the domestic economy. FDA data cited in the probe revealed that approximately 53 percent of patented pharmaceutical products distributed in the United States are manufactured abroad. The administration has maintained that domestic manufacturing capabilities are vital to supporting national defense requirements and ensuring uninterrupted access to life-saving medications.
The tariff plan for generic drugs aligns with previously established trade measures, such as the 100 percent tariff on imported patented pharmaceuticals, which is reduced to 20 percent for companies with approved onshoring plans before rising back to 100 percent over four years. To support these economic measures, the administration has also taken regulatory steps, including a May 2025 executive order directing the FDA to streamline approval processes for domestic plants and instructing the Environmental Protection Agency to expedite the construction of critical pharmaceutical facilities.
